{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:37:36Z","timestamp":1781300256997,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11864-020-00766-4","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T10:02:35Z","timestamp":1593856955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-6705","authenticated-orcid":false,"given":"Emanuela","family":"Palmerini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Lodewijk","family":"Staals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Baxter","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Maria","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Longhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Lor","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,4]]},"reference":[{"issue":"4","key":"766_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/CCO.0b013e328354c129","volume":"24","author":"DM Thomas","year":"2012","unstructured":"Thomas DM. RANKL, denosumab, and giant cell tumor of bone. Curr Opin Oncol. 2012;24(4):397\u2013403.2.","journal-title":"Curr Opin Oncol"},{"issue":"12","key":"766_CR2","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1185\/03007995.2010.533651","volume":"26","author":"EM Lewiecki","year":"2010","unstructured":"Lewiecki EM. Clinical use of denosumab for the treatment for postmenopausal osteoporosis. Curr Med Res Opin. 2010;26(12):2807\u201312.","journal-title":"Curr Med Res Opin"},{"issue":"16","key":"766_CR3","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","volume":"18","author":"DG Branstetter","year":"2012","unstructured":"Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012;18(16):4415\u201324.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"766_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S1470-2045(10)70170-4","volume":"11","author":"D Thomas","year":"2010","unstructured":"Thomas D, Carriere P, Jacobs I. Safety of denosumab in giant-cell tumour of bone. Lancet Oncol. 2010;11(9):815.","journal-title":"Lancet Oncol"},{"issue":"9","key":"766_CR5","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3109\/0284186X.2014.910313","volume":"53","author":"J Martin-Broto","year":"2014","unstructured":"Martin-Broto J, Cleeland CS, Glare PA, Engellau J, Skubitz KM, Blum RH, et al. Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study. Acta Oncol. 2014;53(9):1173\u20139.","journal-title":"Acta Oncol"},{"issue":"9","key":"766_CR6","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","volume":"14","author":"S Chawla","year":"2013","unstructured":"Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label,parallel-group, phase 2 study. Lancet Oncol. 2013;14(9):901\u20138.","journal-title":"Lancet Oncol."},{"key":"766_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.01.006","volume":"59","author":"F Traub","year":"2016","unstructured":"Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Eur J Cancer. 2016;59:1\u201312.","journal-title":"Eur J Cancer"},{"issue":"1","key":"766_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aott.2016.03.004","volume":"51","author":"MA Deveci","year":"2017","unstructured":"Deveci MA, Payda\u015f S, G\u00f6nl\u00fc\u015fen G, \u00d6zkan C, Bi\u00e7er \u00d6S, Tekin M. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: prospective study of 14 cases. Acta Orthop Traumatol Turc. 2017;51(1):1\u20136.","journal-title":"Acta Orthop Traumatol Turc"},{"key":"766_CR9","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s11999-015-4249-2","volume":"473","author":"L Aponte-Tinao","year":"2015","unstructured":"Aponte-Tinao L, Piuzzi NS, Roitman P, Farfalli GL. A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab. Clin Orthop Relat Res. 2015;473:3050\u20135.","journal-title":"Clin Orthop Relat Res"},{"key":"766_CR10","doi-asserted-by":"publisher","unstructured":"Broehm JC, Garbrecht EL, Wood J, Bocklage T. Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab. Case Rep Med. 2015. https:\/\/doi.org\/10.1155\/2015\/767198.","DOI":"10.1155\/2015\/767198"},{"key":"766_CR11","doi-asserted-by":"publisher","unstructured":"Alaqaili SI, Abduljabbar AM, Altaho AJ, Khan AA, Alherabi JA. Malignant sarcomatous transformation of benign giant cell tumor of bone after treatment with denosumab therapy: a literature review of reported cases. Cureus. 2018. https:\/\/doi.org\/10.7759\/cureus.3792.","DOI":"10.7759\/cureus.3792"},{"issue":"11","key":"766_CR12","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/jjco\/hyx112","volume":"47","author":"S Tsukamoto","year":"2017","unstructured":"Tsukamoto S, Righi A, Vanel D, Honoki K, Donati DM, Errani C. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab. Jpn J Clin Oncol. 2017;47(11):1090\u20136.","journal-title":"Jpn J Clin Oncol"},{"key":"766_CR13","doi-asserted-by":"publisher","unstructured":"Park A, Cipriano CA, Hill K, Kyriakos M, McDonald DJ. Malignant transformation of a giant cell tumor of bone treated with denosumab. JBJS Case Connect. 2016. https:\/\/doi.org\/10.2106\/JBJS.CC.16.00024.","DOI":"10.2106\/JBJS.CC.16.00024"},{"key":"766_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/COC.0000000000000504","volume":"42","author":"DD Greenberg","year":"2019","unstructured":"Greenberg DD, Lee FY. Bisphosphonate-loaded bone cement as a local adjuvant therapy for giant cell tumor of bone a 1 to 12-year follow-up study. Am J Clin Oncol. 2019;42:231\u20137.","journal-title":"Am J Clin Oncol"},{"key":"766_CR15","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00432-008-0370-x","volume":"134","author":"M Balke","year":"2008","unstructured":"Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008;134:969\u201378.","journal-title":"J Cancer Res Clin Oncol"},{"key":"766_CR16","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.2106\/JBJS.D.02771","volume":"90","author":"A Knochentumoren","year":"2008","unstructured":"Knochentumoren A, Becker WT, Dohle J, et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am. 2008;90:1060\u20137.","journal-title":"J Bone Joint Surg Am"},{"key":"766_CR17","doi-asserted-by":"publisher","first-page":"586090","DOI":"10.1155\/2010\/586090","volume":"2010","author":"H Algawahmed","year":"2010","unstructured":"Algawahmed H, Turcotte R, Farrokhyar F, Ghert M. High-speed burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: a systematic review and meta-analysis. Sarcoma. 2010;2010:586090.","journal-title":"Sarcoma"},{"issue":"1","key":"766_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/17453670710014815","volume":"79","author":"AH Kivioja","year":"2008","unstructured":"Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HC, et al. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian sarcoma group study of 294 patients followed for a median time of 5 years. Acta Orthop. 2008;79(1):86\u201393.","journal-title":"Acta Orthop"},{"issue":"12","key":"766_CR19","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","volume":"20","author":"S Chawla","year":"2019","unstructured":"\u2022\u2022 Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open label, phase 2 study. Lancet Oncol. 2019;20(12):1719\u201329. Largest phase 2 clinical trial on denosumab for giant cell tumor of bone, including 532 patients, showing long-term efficacy and safety of the treatment.","journal-title":"Lancet Oncol"},{"issue":"10","key":"766_CR20","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1093\/annonc\/mdv307","volume":"26","author":"T Ueda","year":"2015","unstructured":"Ueda T, Morioka H, Nishida Y, Kakunaga S, Tsuchiya H, Matsumoto Y, et al. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. Ann Oncol. 2015;26(10):2149\u201354.","journal-title":"Ann Oncol"},{"issue":"3","key":"766_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/0284186X.2016.1278305","volume":"56","author":"K Boye","year":"2017","unstructured":"Boye K, Jebsen NL, Zaikova O, Knobel H, L\u00f8ndalen AM, Trovik CS, et al. Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort. Acta Oncol. 2017;56(3):479\u201383.","journal-title":"Acta Oncol"},{"key":"766_CR22","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1245\/s10434-015-4634-9","volume":"22","author":"P Rutkowski","year":"2015","unstructured":"Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 2015;22:2860\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"766_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1136\/jclinpath-2015-203248","volume":"69","author":"I Girolami","year":"2016","unstructured":"Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, et al. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J Clin Pathol. 2016;69(3):240\u20137.","journal-title":"J Clin Pathol"},{"issue":"6","key":"766_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2106\/JBJS.17.00057","volume":"100","author":"C Errani","year":"2018","unstructured":"Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, et al. Denosumab may increase the risk of local recurrence in patients with Giant-cell tumor of bone treated with curettage. J Bone Joint Surg Am. 2018;100(6):496\u2013504.","journal-title":"J Bone Joint Surg Am"},{"issue":"10","key":"766_CR25","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00402-019-03167-x","volume":"139","author":"G Luengo-Alonso","year":"2019","unstructured":"\u2022 Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg. 2019;139(10):1339\u201349. Systematic review of the literature including 1095 patients, showing clinical and radiologic responses, and less morbid surgery after denosumab.","journal-title":"Arch Orthop Trauma Surg"},{"issue":"9","key":"766_CR26","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s11999.0000000000000104","volume":"476","author":"G Scoccianti","year":"2018","unstructured":"Scoccianti G, Totti F, Scorianz M, Baldi G, Roselli G, Beltrami G, et al. Preoperative denosumab with curettage and cryotherapy in giant cell tumor of bone: is there an increased risk of local recurrence? Clin Orthop Relat Res. 2018;476(9):1783\u201390.","journal-title":"Clin Orthop Relat Res"},{"issue":"9","key":"766_CR27","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s11999.0000000000000243","volume":"476","author":"MG Agarwal","year":"2018","unstructured":"Agarwal MG, Gundavda MK, Gupta R, Reddy R. Does denosumab change the giant cell tumor treatment strategy? Lessons learned from early experience. Clin Orthop Relat Res. 2018;476(9):1773\u201382.","journal-title":"Clin Orthop Relat Res"},{"issue":"2","key":"766_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1302\/0301-620X.101B2.BJJ-2018-0907.R2","volume":"101-B","author":"A Puri","year":"2019","unstructured":"Puri A, Gulia A, Hegde P, Verma V, Rekhi B. Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone. Bone Joint J. 2019;101-B(2):170\u20137.","journal-title":"Bone Joint J"},{"key":"766_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12957-016-1034-y","volume":"14","author":"DA M\u00fcller","year":"2016","unstructured":"M\u00fcller DA, Beltrami G, Scoccianti G, Campanacci DA, Franchi A, Capanna R. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series. World J Surg Oncol. 2016;14:281.","journal-title":"World J Surg Oncol"},{"key":"766_CR30","first-page":"427","volume-title":"Pathology and genetics of tumours of soft tissue and bone","author":"F CDM","year":"2002","unstructured":"CDM F, Unni KK, Mertens F, World Health Organization, International Agency for Research on Cancer. Pathology and genetics of tumours of soft tissue and bone. Geneva: IARC Press; 2002. p. 427."},{"key":"766_CR31","doi-asserted-by":"crossref","unstructured":"Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP. Giant cell tumor of bone. Am J Clin Oncol. 2006;29(1):96\u20139 Review.","DOI":"10.1097\/01.coc.0000195089.11620.b7"},{"key":"766_CR32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4055\/cios.2019.11.3.352","volume":"11","author":"PS Chinder","year":"2019","unstructured":"Chinder PS, Hindiskere S, Doddarangappa S, Pal U. Evaluation of local recurrence in giant-cell tumor of bone treated by neoadjuvant denosumab. Clin Orthop Surg. 2019;11:352\u201360.","journal-title":"Clin Orthop Surg"},{"key":"766_CR33","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.ejso.2018.03.020","volume":"44","author":"P Rutkowski","year":"2018","unstructured":"\u2022 Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, et al. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. Eur J Surg Oncol. 2018;44:1384\u201390. Multicenter study including 138 patients showing the surgical downstaging effect of denosumab.","journal-title":"Eur J Surg Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-020-00766-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T23:08:40Z","timestamp":1625353720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-020-00766-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,4]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-00766-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,4]]},"assertion":[{"value":"4 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Emanuela Palmerini has received compensation from Daiichi Sankyo, Deciphera, Lilly, and EUSA Pharma for service as a consultant and has received non-financial support from PharmaMar.Eric Lodewijk Staals declares that he has no conflict of interest.Louis Baxter Jones declares that he has no conflict of interest.Davide Maria Donati declares that he has no conflict of interest.Alessandra Longhi declares that she has no conflict of interest.R. Lor Randall declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"68"}}